

Jon M Wigginton

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10764562/jon-m-wigginton-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

21,870
citations

24
h-index

30
g-index

30
ext. papers

24,938
ext. citations

11.4
avg, IF

5.61
L-index

#	Paper	IF	Citations
29	Combination immunotherapy: a road map 2017 , 5, 16		228
28	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting 2017 , 5,		8
27	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy 2017 , 5, 44		139
26	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
25	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2004-12	2.2	859
24	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1020-30	2.2	1684
23	Nivolumab plus ipilimumab in advanced melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 122-33	59.2	3118
22	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. <i>Journal of Clinical Oncology</i> , 2013 , 31, CRA9006-CRA9006	2.2	34
21	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2443-54	59.2	8684
20	High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. <i>Cancer Investigation</i> , 2012 , 30, 343-63	2.1	8
19	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2455-65	59.2	5527
18	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. <i>Immunology</i> , 2011 , 132, 226-39	7.8	90
17	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011 , 17, 3064-76	12.9	87
16	Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. <i>Journal of Immunology</i> , 2009 , 182, 4328-38	5.3	75
15	Immunotherapy of cancer by IL-12-based cytokine combinations. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1705-21	5.4	167
14	Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 190-202	9.7	12
13	Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. <i>Journal of Immunology</i> , 2006 , 176, 6302-12	5.3	31

12	Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors. <i>Journal of Immunotherapy</i> , 2006 , 29, 151-64	5	7
11	IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. <i>Journal of Immunology</i> , 2004 , 173, 7170-82	5:3	133
10	Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. <i>Journal of Immunology</i> , 2003 , 170, 2727-33	5:3	93
9	Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. <i>Journal of Immunology</i> , 2002 , 169, 4467-74	5:3	58
8	IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 513-24	5:4	39
7	Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2). <i>Journal of Immunology</i> , 2001 , 166, 3763-70	5:3	31
6	Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. <i>Journal of Immunology</i> , 2001 , 166, 1156-68	5:3	42
5	IFN- γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2001 , 108, 51-62	15:9	98
4	IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. <i>Journal of Immunology</i> , 2000 , 164, 231-9	5:3	63
3	Interleukin-12: murine models of a potent antitumor agent. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 266-74	6:5	24
2	Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 434-9	6:5	8
1	Antitumor activity of interleukin 12 in preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38 Suppl, S16-21	3:5	66